Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion
|
|
- Alexina Leonard
- 5 years ago
- Views:
Transcription
1 Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO Avelumab 200 mg/10 ml Concentrate for Solution for Infusion Marketing Authorisation Number Marketing Authorisation Holder: Merck (Schweiz) AG, Zug Disclaimer: The Risk Management Plan (RMP) is a comprehensive document submitted a spart oft he application dossier for market approval of a medicine. The RMP summary contains information on the medicine s safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them. The RMP summary of Bavencio is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the Arzneimittelinformation/Information sur le médicament approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization. Please note that the reference document which is valid and relevant for the effective and safe use of Bavencio in Switzerland is the Arzneimittelinformation/Information sur le medicament (see approved and authorized by Swissmedic. Merck (Schweiz) AG is fully responsible for the accuracy and correctness of the content of the published summary RMP of Bavencio.
2 VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Merkel cell carcinoma (MCC, also known as cutaneous neuro-endocrine carcinoma) is a rare type of skin cancer that starts in neuro-endocrine cells called Merkel cells. MCC usually appears as a painless tumor on the head and neck, but can also be found on the arms and legs, and sometimes on other parts of the body. In Europe, MCC accounts for less than 1% of all skin malignancies and about 4.0 per 100,000 people are affected by MCC in Europe. MCC predominantly affects the white population, affects men more often than women and occurs more frequently in elderly individuals and those with immunodeficiency. Additional risk factors include previous cancer disease, Merkel cell polyomavirus infection, and ultraviolet light exposure. MCC is a debilitating and life-threatening disease because it grows rapidly and spreads (metastasizes) quickly to other parts of the body. Once this cancer has spread, it has very poor long-term survival. VI.2.2 Summary of Treatment Benefits Bavencio contains the active substance avelumab. The medicine has been shown to be effective in treating adult patients with progressing spreading Merkel Cell Carcinoma (MCC). In an ongoing study including two parts, patients received Bavencio at a dose of 10 milligram per kilogram (mg/kg) every two weeks until cancer progression or the occurrence of side effects. The study looked at how the patient s cancer responded to treatment and how long responses persisted. The first part of the study (part A) included 88 patients who were previously treated with at least one other anti-cancer drug (chemotherapy). Twenty-nine out of 88 patients (33.0 %) responded to Bavencio treatment with improvement of their disease (tumor size decreased). This response was durable and was still present after 6 months in 93 % of patients who had a response to treatment and after 12 months in 71 % of patients who had a response to treatment. The second part of the study (part B) will include 112 subjects who were not previously treated with any chemotherapy for their metastatic cancer. Results from 29 subjects show that 62.5% of subjects responded to Bavencio treatment (their disease improved). The study is ongoing and data with longer follow-up will be reported in the future. 1
3 VI.2.3 Unknowns Relating to Treatment Benefits In both supporting studies the majority of patients were adult or elderly white Caucasians. Avelumab was not studied in special patients with autoimmune disease, infections with HIV, hepatitis B or hepatitis C, organ transplant recipients, or pregnant or lactating patients. VI.2.4 Summary of Safety Concerns Important identified risks of the lung (pneumonitis) of the liver (hepatitis) In the supporting clinical trials, 1.2% (21/1738) of the patients developed inflammation of the lung (pneumonitis). Pneumonitis can be serious, lifethreatening and can have a fatal outcome. Signs and symptoms may include new or worsening cough and, breathing difficulties. In the supporting clinical trials 0.9% (16/1738) of the patients developed inflammation of the liver (hepatitis). Hepatitis can be serious, lifethreatening and can have a fatal outcome. Signs and symptoms may include yellowing of the skin or in the whites of the eyes, severe nausea, or vomiting, pain on the right side of the stomach area (abdomen), drowsiness, tiredness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual. signs and symptoms of pneumonitis and may delay or completely stop treatment with avelumab depending on the severity of symptoms. Physicians should seek early confirmation of diagnosis. By early recognition and by following recommended treatment guidelines serious complications may be prevented. changes in liver function and signs and symptoms of hepatitis and may delay or completely stop treatment with avelumab depending on the severity of symptoms. By early recognition and by following recommended treatment guidelines serious complications may be prevented. 2
4 of the large intestine (colitis) Immune-related disorders of hormone producing glands (so-called endocrinopathies, especially of the thyroid, adrenal glands, endocrine pancreas, and pituitary gland) In the supporting clinical trials, 1.5% (26/1738) of the patients developed inflammation of the large intestine (colitis). Colitis can be serious. Signs and symptoms may include diarrhea (loose stools) or more bowel movements than usual, blood in stools or dark, tarry, sticky stools and severe stomach area (abdomen) pain or tenderness. In the supporting clinical trials, 5.6% (98/1738) of the patients developed thyroid disorders, 0.5% (8/1738) adrenal insufficiency, less than 0.1 % (2/1738) type 1 diabetes mellitus and less than 0.1% (1/1738) hypopituitarism. Thyroid disorders, adrenal insufficiency,type 1 diabetes mellitus and hypopituitarism can be serious and lifethreatening. Signs and symptoms of immunerelated disorders of hormone producing glands may include rapid heartbeat, feeling cold, increased sweating, constipation, extreme tiredness, weight gain or weight loss, very low blood pressure, headache, feeling more hungry than usual, increased thirst and urination, dizziness, nausea or vomiting, changes in mood or behavior, such as irritability or forgetfulness and stomach area (abdomen) pain. signs and symptoms of colitis and may delay or completely stop treatment with avelumab depending on the severity of symptoms. Any other causes of colitis should be excluded. By early recognition and by following recommended treatment guidelines serious complications may be prevented. changes in thyroid and other endocrine function and for signs and symptoms of thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, and pituitary dysfunction, and may delay or completely stop treatment with avelumab depending on the severity of symptoms. By early recognition and by following recommended treatment guidelines serious complications may be prevented. 3
5 of the muscles (myositis) of the heart (myocarditis) Guillain-Barre Syndrome Uveitis In the supporting clinical trials 0.5% (9/1738) of the patients developed inflammation of the muscles. Myositis can be serious. Signs and symptoms of myositis may include muscle weakness and muscle pain. called immune -related reactions) in In the supporting clinical trials, no patient developed immune-related myocarditis. In other clinical studies in the clinical trial program, single cases have been reported. Myocarditis can be serious, lifethreatening and can have a fatal outcome. Signs and symptoms of myocarditis may include trouble breathing, dizziness or fainting, fever, chest pain and chest tightness or flu-like symptoms. In the supporting clinical trials a single subject experienced Guillain-Barre Syndrome. Guillain-Barre Syndrome can be serious. In the avelumab supporting clinical trials a single subject experienced Uveitis. Uveitis can be serious. Uveitis is an inflammation of eye. signs and symptoms of myositis and may delay or completely stop treatment with avelumab depending on the severity of symptoms. By early recognition and by following recommended treatment guidelines further exacerbations may be prevented. signs and symptoms of myocarditis with subsequent cardiologic consultation and laboratory investigations to ensure the initiation of appropriate treatment measures at an early stage. Avelumab should be delayed for new-onset moderate or severe cardiac signs or symptoms and corticoids should be administered. Avelumab has to be completely stopped for immune-related myocarditis. By early recognition and by following recommended treatment guidelines serious complications may be prevented. signs and symptoms of Guillain-Barre Syndrome and may initiate appropriate diagnostic and therapeutic measures in case of suspicion of the syndrome. signs and symptoms of uveitis and may initiate appropriate diagnostic and therapeutic measures in case of suspicion of uveitis. 4
6 of the kidney (nephritis) and renal dysfunction Severe reactions related to the administration of avelumab (infusion-related reactions) Important potential risks To date, in the supporting clinical studies, a single patient suffered immune-related inflammation of the kidney or renal dysfunction. Signs and symptoms of kidney (nephritis) and renal dysfunction may include abnormal kidney function tests, urinate less than usual, blood in your urine, or swelling in your ankles reactions during administration. In the supporting clinical trials, 0.7% (12/1738) of the patients developed severe reactions during the infusion. Infusion-related reactions can be serious and life-threatening. Signs and symptoms of severe reactions during infusion may include chills or shaking, rash, hives, flushing, shortness of breath, low blood pressure, dizziness, fever, back or neck pain and abdominal pain. signs and symptoms of nephritis and renal dysfunction and may initiate appropriate diagnostic and therapeutic measures in case of suspicion of nephritis or renal dysfunction. Premedication with an antihistamine and with paracetamol should be considered for the first four infusions. signs and symptoms of infusion-related reactions. Treatment with avelumab should be completely stopped if severe ( Grade 3) infusion-related reactions occur. By early recognition and by following recommended treatment guidelines serious complications may be prevented. Risk Other immune-related events (including immune-related encephalitis, myasthenic syndrome and pancreatitis); Severe cutaneous reactions Development of antibodies against avelumab (immunogenicity) What is known (Including reason why it is considered a potential risk) To date, in the supporting clinical studies, no cases of immune-related encephalitis, myasthenic syndrome and pancreatitis have been reported for avelumab. Severe cutaneous (skin) reactions are a potential class effect of checkpoint inhibitors, the pharmacological class to which avelumab belongs. Severe cutaneous reactions are a diverse group of adverse events. A few events of severe skin reactions (e.g. severe rash) have been observed in relation to avelumab. defense system). Antibodies such as avelumab may induce the immune system to produce antibodies against avelumab. This may be associated with infusion reactions or reduced effectiveness. Up to date in the supporting clinical studies avelumab has shown a low potential to induce the formation of antibodies. 5
7 Risk Effects on the developing baby (embryofetal toxicity) What is known (Including reason why it is considered a potential risk) To date, there are no cases of avelumab exposure during pregnancy. Based on avelumab s mechanism of action and data of animal models, there is a potential risk that avelumab may cause fetal harm when administered to a pregnant woman. Missing information Risk Safety in patients with Autoimmune disease Safety in patients with HIV, Hepatitis B or C infections Safety in patients with Organ transplants Use during lactation What is known To-date, there is no experience in patients with autoimmune disease. To-date, there is no experience in patients with HIV, hepatitis B or C infections. To date, there is limited experience in avelumab in subjects with prior organ transplantation. It is unknown whether avelumab is secreted in human breast milk. Women should be advised to discontinue breast feeding during treatment with avelumab, and for at least 1 months after the last dose of avelumab Long-term safety The duration of therapy with avelumab in clinical studies ranged up to 138 weeks. Safety and efficacy in immune compromised patients To-date, there is limited experience regarding the efficacy and safety of avelumab in patients with underlying immunosuppressive conditions VI.2.5 Summary of Additional Risk Minimization Measures by Safety Concern All medicines have a SmPC which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the Package Leaflet. The measures in these documents are known as routine risk minimisation measures. This medicine has special conditions and restrictions for its safe and effective use (additional risk minimization measures). How they are implemented in each country, however, will depend upon agreement between the marketing authorization holder and the national authorities. These additional risk minimization measures are for the following risks (safety concerns): 1. Immune related adverse reactions 2. Severe infusion related reactions 6
8 Risk Minimization Measures Objective and rationale Increase the awareness about the identified and potential immune related adverse events associated with avelumab use. Prevent or minimize occurrence of the above-listed risks in patients receiving avelumab and reinforce the dose modifications and treatment guidelines provided in the product labeling. Proposed action: In addition to the mandatory Summary of Product Characteristics (SmPC) and package leaflet (Pl), Merck will produce appropriate educational materials to raise awareness for immune-related adverse reactions Aspects to be emphasized in the educational materials include: The risks associated with avelumab (immune related adverse reactions and IRRs) The importance of monitoring patients for signs and symptoms suggestive of immune related adverse events and IRRs and the actions to take in the case of the occurrence of such events (dose modifications and treatment) The importance of patient counseling in detecting signs and symptoms suggestive of immune related adverse events and reporting them to their healthcare professionals so that appropriate measures can be initiated as soon as possible VI.2.6 Planned Post Authorization Development Plan Study (type and study number) Objectives Efficacy uncertainties addressed Status (planned, started) Date for submission of interim or final reports EMR Part B A Phase II, openlabel, multicenter trial to investigate the clinical activity and safety of avelumab (MSB C) in subjects with Merkel cell carcinoma The primary endpoint is durable response, defined as objective response (CR or PR) according to RECIST 1.1, determined by an Independent Endpoint Review Committee, with duration of at least 6 months. Assess the objective response (CR or PR) with duration of at least 6 months in the first line setting in subjects with metastatic Merkel Cell Carcinoma Started Q Q VI.2.7 Summary of Changes to the Risk Management Plan over Time Not applicable. 7
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationSummary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)
EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in
More informationSummary of the risk management plan (RMP) for Opdivo (nivolumab)
EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure
More informationPackage leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab
Package leaflet: Information for the patient Bavencio 20 mg/ml concentrate for solution for infusion avelumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationFor the Patient: USMAVNIV
For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationFor the Patient: ULUAVPMB
For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationNivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions
Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team
Discussing TECENTRIQ (atezolizumab) with your healthcare team What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ
More informationBRISTOL-MYERS SQUIBB RESEARCH & DEVELOPMENT SWISS SUMMARY OF THE RISK MANAGEMENT PLAN FOR NIVOLUMAB (NIVOLUMAB IS THE ACTIVE SUBSTANCE IN OPDIVO )
BRISTOL-MYERS SQUIBB RESEARCH & DEVELOPMENT SWISS SUMMARY OF THE RISK MANAGEMENT PLAN FOR NIVOLUMAB (NIVOLUMAB IS THE ACTIVE SUBSTANCE IN OPDIVO ) Version Number: 7 Document Date: 13-Dec-2018 Bristol-Myers
More informationGiving appropriate patients another chance to fight OPDIVO
For dmmr/msi-h Colorectal Cancer (CRC) All individuals depicted are models used for illustrative purposes only. Who is OPDIVO for? OPDIVO is a prescription medicine used to treat colorectal cancer (a type
More informationYOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)
YOUR GUIDE TO TECENTRIQ (atezolizumab) For previouslytreated advanced non-small cell lung cancer (NSCLC) ABOUT THIS BOOKLET This booklet is for people with advanced non-small cell lung cancer (NSCLC) who
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr OPDIVO is used to treat: Adults with skin cancer (advanced melanoma) who have not been treated and who have specific
More informationVictoza (liraglutide) solution for injection 6 mg/ml
Page: 1 of 11 Victoza (liraglutide) solution for injection 6 mg/ml Summary of the risk management plan (RMP) for Victoza Author: Novo Nordisk Pharma AG Page: 2 of 11 Table of Contents Page Table of Contents...
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationZinplava Swiss Risk Management Plan Summary V1.5. Swiss Summary of the Risk Management Plan (RMP) for. Zinplava. (Bezlotoxumab 1000mg)
Swiss Summary of the Risk Management Plan (RMP) for (Bezlotoxumab 1000mg) Concentrate for solution for infusion Version 1.5 (November 2016) The Risk Management Plan (RMP) is a comprehensive document submitted
More informationSwiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab)
Swiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab) RMP Summary: Version 1, April 2017 EU RMP: Version 3.2, November 2016 Page 1 of 13 The Risk Management Plan (RMP) is a comprehensive
More informationSwiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)
Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 1, November 2017 EU RMP: Version 1.0, November 2016 Page 1 of 6 The Risk Management Plan (RMP) is a comprehensive
More informationMaviret (Glecaprevir / Pibrentasvir)
Swiss Summary of the Risk Management Plan (RMP) Maviret (Glecaprevir / Pibrentasvir) 100 mg/40 mg Film-coated tablets Version 1.0 (Dec 2016) AbbVie AG 1 Disclaimer The Risk Management Plan (RMP) is a comprehensive
More informationsystem to help fight cancer Working with your immune
KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist ABOUT About KEYTRUDA How KEYTRUDA works Name How KEYTRUDA works with your
More informationSummary of the risk management plan (RMP) for Gazyvaro (obinutuzumab)
EMA/319729/2014 Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab) This is a summary of the risk management plan (RMP) for Gazyvaro, which details the measures to be taken in order to
More informationRisk Management Plan Summary
Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,
More informationsystem to help fight cancer Working with your immune
KEYTRUDA Working with your immune system to help fight cancer www.fightcancer.co.nz CONTACT DETAILS Your Oncologist/Specialist Name Phone Phone (after hours) Your Specialist Nurse Name Phone Phone (after
More informationSummary of risk management plan for OPDIVO (nivolumab)
Summary of risk management plan for OPDIVO (nivolumab) This is a summary of the risk management plan (RMP) for OPDIVO. The RMP details important risks of OPDIVO, how these risks can be minimized, and how
More informationSummary of the risk management plan (RMP) for Kyprolis (carfilzomib)
EMA/639793/2015 Summary of the risk management plan (RMP) for Kyprolis (carfilzomib) This is a summary of the risk management plan (RMP) for Kyprolis, which details the measures to be taken in order to
More informationSummary of risk management plan for OPDIVO (nivolumab)
Summary of risk management plan for OPDIVO (nivolumab) This is a summary of the risk management plan (RMP) for OPDIVO. The RMP details important risks of OPDIVO, how these risks can be minimized, and how
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION KEYTRUDA has been issued marketing authorization with conditions for the following patients, pending the results of
More informationWhat do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Durvalumab Brand Names: US Imfinzi Brand Names: Canada Imfinzi What is this drug used for? It is used to treat cancer in the bladder or urinary tract. It is used to treat
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More informationPublic Risk Management Plan (RMP) Summary
Tecentric (Atezolizumab) 1200 mg/20 ml, Konzentrat zur Herstellung einer Infusionslösung Zul.-Nr. 66 152 Public Risk Management Plan (RMP) Summary Document Version: 2.0 Document Date: 22.01.2018 Based
More informationPLENADREN EU-RMP VERSION 3.2. Elements for a Public Summary. Overview of Disease Epidemiology
PLENADREN EU-RMP VERSION 3.2 VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology PLENADREN contains hydrocortisone and is used to treat adrenal insufficiency (AI) in adults. AI occurs
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationRisk Management Plan Summary
Risk Management Plan Summary Terrosa Teriparatide 20 micrograms/80 microliters Solution for injection Document Version: 1.0 Document Date: 24.01.2019. Based on EU RMP Version: 1.2 Marketing Authorization
More informationPackage leaflet: Information for the patient. KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab
Package leaflet: Information for the patient KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationSwiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)
Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab) RMP Summary: Version 1, March 2017 EU RMP: Version 2, 26.5.2016 The Risk Management Plan (RMP) is a comprehensive document submitted
More informationCabometyx 20/40/60 mg. Film-coated tablets. Elements for a Public Summary Summary of the Safety Risk Management Plan (RMP)
PAGE 1/9 Cabometyx 20/40/60 mg (Cabozantinib) Film-coated tablets Elements for a Public Summary Summary of the Safety Management Plan (RMP) Reference RMP EU RMP version 2.0 Products concerned (brand names):
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationHave a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider
Have a healthy discussion Use this guide to start a conversation with your healthcare provider MAKE THE CONVERSATION COUNT Here are some things you may want to reflect on and discuss with your healthcare
More informationSUMMARY OF THE RISK MANAGEMENT PLAN FOR. BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion.
SUMMARY OF THE RISK MANAGEMENT PLAN FOR BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion. This RMP Summary is based on Part VI of the EU RMP for BESPONSA (Inotuzumab
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationImmune-Mediated Adverse Events Management Handbook
Immune-Mediated Adverse Events Management Handbook Your guide to addressing the immune-mediated adverse events (imaes) associated with patients taking PD-L1 inhibition therapy Indications and Usage IMFINZI
More informationSummary of the risk management plan (RMP) for Ketoconazole HRA (ketoconazole)
EMA/609213/2014 Summary of the risk management plan (RMP) for Ketoconazole HRA (ketoconazole) This is a summary of the risk management plan (RMP) for Ketoconazole HRA, which details the measures to be
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationWhat do I need to tell my doctor BEFORE I take this drug?
PATIENT & CAREGIVER EDUCATION Pembrolizumab Brand Names: US Keytruda Brand Names: Canada Keytruda What is this drug used for? It is used to treat cancer. What do I need to tell my doctor BEFORE I take
More informationSummary of the risk management plan (RMP) for Portrazza (necitumumab)
EMA/33513/2016 Summary of the risk management plan (RMP) for Portrazza (necitumumab) This is a summary of the risk management plan (RMP) for Portrazza, which details the measures to be taken in order to
More informationSwiss Summary of the Risk Management Plan (RMP) for Ongentys (opicapone) 50 mg hard capsules
Swiss Summary of the Risk Management Plan (RMP) for Ongentys (opicapone) 50 mg hard capsules Final Version 1.0 (08 June 2018) The Risk Management Plan (RMP) is a comprehensive document submitted as part
More informationMETHYLDOPA 250 mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER METHYLDOPA 250 mg Film-coated Tablets METHYLDOPA This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationVI.2 Elements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Febuxostat is a medicine used in adults with gout to reduce high levels of uric acid in the blood. Gout results from a build up
More informationOlumiant. (baricitinib) 2 mg and 4 mg, film-coated tablets. Summary of Risk Management Plan (RMP) Version 2.0, Page 1
Olumiant (baricitinib) 2 mg and 4 mg, film-coated tablets Summary of Risk Management Plan (RMP) Version 2.0, 16-04-2018 Page 1 Summary of the risk management plan (RMP) for Olumiant (baricitinib) The Risk
More informationSummary of the risk management plan (RMP) for Cresemba (isavuconazole)
EMA/576866/2015 Summary of the risk management plan (RMP) for Cresemba (isavuconazole) This is a summary of the risk management plan (RMP) for Cresemba, which details the measures to be taken in order
More informationWhat You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide
For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV is a virus that attacks the immune system (the body s natural defences) and weakens it by destroying certain white blood cells
More informationSummary of the Risk Management Plan (RMP) for Vizamyl (flutemetamol 18 F)
Summary of the Risk Management Plan (RMP) for Vizamyl (flutemetamol 18 F) Version 1 October 2016 Disclaimer: The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application
More informationVildagliptin belongs to a group of medicines called oral antidiabetics.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Vildagliptin belongs to a group of medicines called oral antidiabetics. Vildagliptin is used in a certain form of diabetes (type
More informationSummary of the risk management plan (RMP) for Evotaz (atazanavir/cobicistat)
EMA/391330/2015 Summary of the risk management plan (RMP) for Evotaz (atazanavir/cobicistat) This is a summary of the risk management plan (RMP) for Evotaz, which details the measures to be taken in order
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nevirapine is used for antiretroviral combination therapy of Human Immunodeficiency Virus (HIV) infection. Human immunodeficiency
More informationZerlinda (MRP DK/H/2265/001)
Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread
More informationProphylaxis of acute transplant rejection in patients receiving allogeneic renal transplants:
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants: Over 1 million people worldwide
More informationSwiss Summary of the Risk Management Plan (RMP) for. Vosevi, film-coated tablets
Swiss Summary of the Management Plan (RMP) for, film-coated tablets (Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination) 400mg/100mg/100mg Version 1.0 (February 2018) final Based on EU RMP version
More informationInlyta (axitinib) for Kidney Cancer
Inlyta (axitinib) for Kidney Cancer Inlyta is a medication used to treat advanced kidney cancer in adults when one prior drug treatment for this disease has not worked Dosage: 5mg taken twice a day How
More informationDrug Regulatory Affairs. Praluent. Summary of the Risk Management Plan (RMP) for Praluent (alirocumab)
Drug Regulatory Affairs Praluent Summary of the Risk Management Plan (RMP) for Praluent (alirocumab) Document version: 02 Document date: MAY 2018 Summary of the risk management plan (RMP) for Praluent
More informationFor males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.
PATIENT INFORMATION INLYTA (in-ly-ta) (axitinib) tablets Read this Patient Information before you start taking INLYTA and each time you get a refill. There may be new information. This information does
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET PROSTATIN (OCTREOTIDE ACETATE INJECTION 10mcg, 50mcg) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.
More informationMEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use
MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use If you are taking PegIntron with REBETOL (ribavirin) with or without an approved hepatitis C virus (HCV)
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationFasenra. 30 mg, solution for injection. Summary of the Risk Management Plan (RMP) for Fasenra (Benralizumab)
Fasenra 30 mg, solution for injection Summary of the Risk Management Plan (RMP) for Fasenra (Benralizumab) Document Version: 1.0 Document Date: 08-June-2018 Summary of the risk management plan (RMP) for
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationSummary of the risk management plan (RMP) for Vimizim (elosulfase alfa)
EMA/127543/2014 Summary of the risk management plan (RMP) for Vimizim (elosulfase alfa) This is a summary of the risk management plan (RMP) for Vimizim, which details the measures to be taken in order
More informationMEDICATION GUIDE SUTENT
MEDICATION GUIDE SUTENT (su TENT) (sunitinib malate) capsules Read the Medication Guide that comes with SUTENT before you start taking it and each time you get a refill. There may be new information. This
More informationPage 1 of 5 VERZENIO abemaciclib tablet Eli Lilly and Company AddendaIndex Summary View All Sections HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
More informationOverview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Acne vulgaris (or simply acne) is a common human skin disease, characterized by areas of skin with seborrhea (scaly red skin),
More informationSUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA
SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA Active Substance: Anatomical Therapeutic Code: MAH or Applicant: Medicinal Product(s) to Which this RMP Refers: Products Concerned (Brand Names): Patiromer
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationDo not g ive this drug if your child has an infection or any inflammation.
PATIENT & CAREGIVER EDUCATION Tisagenlecleucel Brand Names: US Kymriah Warning A very bad health problem called cytokine release syndrome (CRS) has happened with this drug. Sometimes, this has been life-threatening
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr SYLVANT pronounced SILL-vant siltuximab for injection Read this carefully before you start taking SYLVANT and each
More informationTrastuzumab (Herceptin )
Trastuzumab (Herceptin ) About This Drug Trastuzumab is used to treat cancer. It is given in the vein (IV) Possible Side Effects Bone marrow depression. This is a decrease in the number of white blood
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Lung cancer is one of the most common types of cancer in European men and women. There are two main types of lung cancer: small
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Actavis is a cancer medicine used to treat two types of lung cancer, malignant pleural mesothelioma and advanced non-small-cell
More informationRydapt. Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin)
Regulatory Affairs Rydapt 25 mg soft capsules Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin) Document version: 01 Document status: Document Date: Final 02-June-2017 1 of 6 Summary of
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationMethotrexate. About This Drug. Possible Side Effects. Warnings and Precautions
Methotrexate About This Drug Methotrexate is used to treat cancer. This drug is given in the vein (IV). Possible Side Effects Soreness of the mouth and throat. You may have red areas, white patches, or
More informationSummary of the risk management plan (RMP) for Pemetrexed Actavis (pemetrexed)
EMA/58503/2016 Summary of the risk management plan (RMP) for Pemetrexed Actavis (pemetrexed) This is a summary of the risk management plan (RMP) for Pemetrexed Actavis, which details the measures to be
More informationVI.2. ELEMENTS FOR A PUBLIC SUMMARY
VI.2. ELEMENTS FOR A PUBLIC SUMMARY VI.2.1 Overview of Disease Epidemiology COCs (Combined Oral Contraceptives) containing DRSP-EE (Drospirenone- Ethinylestradiol) are indicated for the prevention of pregnancy
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type
More information